老年个体淀粉样蛋白与阿尔茨海默病神经退行性变的保护因素评估
这项基于人群的前瞻性队列研究纳入942名70岁及以上老年人,评估 demographics、APOE、智力丰富、中年危险因素及晚年心代谢疾病数量对淀粉样蛋白沉积和AD模式神经退行性变的独立保护作用。结果显示,除人口学和APOE外,仅中年血脂异常与淀粉样蛋白沉积相关;肥胖、吸烟、糖尿病、高血压及心代谢疾病与更严重的AD模式神经退行性变相关,而智力丰富无此关联。在85岁及以上亚组中,多数变量对无AD病理的“卓越老化”有预测效应。
要点
- 淀粉样蛋白沉积与AD模式神经退行性变的保护因素不同。
- 中年血脂异常与淀粉样蛋白沉积相关,而肥胖、吸烟、糖尿病、高血压及心代谢疾病与神经退行性变相关。
- 智力丰富未显示与AD模式神经退行性变相关。
核心结论
- 影响淀粉样蛋白和AD模式神经退行性变的保护因素不同。
- 无AD病理的“卓越老化”可能通过一生中更多保护因素实现,但需进一步研究。
研究设计与样本
- 前瞻性分析942名70岁及以上老年人,来自Mayo Clinic Study of Aging基于人群的纵向队列。
- 纳入对象具有磁共振成像和匹兹堡化合物B-正电子发射断层扫描数据。
主要发现
- 除人口学和APOE基因型外,仅中年血脂异常与淀粉样蛋白沉积相关。
- 肥胖、吸烟、糖尿病、高血压及心脏和代谢疾病与更严重的AD模式神经退行性变相关。
- 智力丰富与AD模式神经退行性变无关。
- 在85岁及以上亚组中,除工作评分和中年高血压外,其他变量预测无AD病理的卓越老化的效应量大于0.2。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While amyloid and neurodegeneration are viewed together as Alzheimer disease pathophysiology (ADP), the factors that influence amyloid and AD-pattern neurodegeneration may be considerably different. Protection from these ADP factors may be important for aging without significant ADP. OBJECTIVE: To identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration in a population-based sample and to test the hypothesis that "exceptional agers" with advanced ages do not have significant ADP because they have protective factors for amyloid and neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS: This cohort study conducted a prospective analysis of 942 elderly individuals (70-≥90 years) with magnetic resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study of cognitive aging in Olmsted County, Minnesota. We operationalized "exceptional aging" without ADP by considering individuals 85 years or older to be without significant evidence of ADP. MAIN OUTCOMES AND MEASURES: We evaluated predictors including demographics, APOE, intellectual enrichment, midlife risk factors (physical inactivity, obesity, smoking, diabetes, hypertension, and dyslipidemia), and the total number of late-life cardiac and metabolic conditions. We used multivariate linear regression models to identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration. Using a subsample of the cohort 85 years of age or older, we computed Cohen d-based effect size estimations to compare the quantitative strength of each predictor variable in their contribution with exceptional aging without ADP. RESULTS: The study participants included 423 (45%) women and the average age of participants was 79.7 (5.9) years. Apart from demographics and the APOE genotype, only midlife dyslipidemia was associated with amyloid deposition. Obesity, smoking, diabetes, hypertension, and cardiac and metabolic conditions, but not intellectual enrichment, were associated with greater AD-pattern neurodegeneration. In the 85 years or older cohort, the Cohen d results showed small to moderate effects (effect sizes > 0.2) of several variables except job score and midlife hypertension in predicting exceptional aging without ADP. CONCLUSIONS AND RELEVANCE: The protective factors that influence amyloid and AD-pattern neurodegeneration are different. "Exceptional aging" without ADP may be possible with a greater number of protective factors across the lifespan but warrants further investigation.
引用
- Vemuri P, Knopman DS, Lesnick TG, et al. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurol. 2017. PMID: 28418521. doi:10.1001/jamaneurol.2017.0244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。